drugset / Trial / NCT05926726
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous armored GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-GPC3 T Cells | Cell therapy | 5e+07 cells | Intravenous |
| Subject | CAR-GPC3 T Cells | Cell therapy | 1e+08 cells | Intravenous |
| Subject | CAR-GPC3 T Cells | Cell therapy | 3e+08 cells | Intravenous |
| Subject | CAR-GPC3 T Cells | Cell therapy | 1e+09 cells | Intravenous |
| Subject | CAR-GPC3 T Cells | Cell therapy | 3e+09 cells | Intravenous |